| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
26.06.2025 13:09:37
|
Why Vor Bio Is Rising In Pre-market?
(RTTNews) - Vor Bio (VOR) and RemeGen Co. announced entry into a license agreement granting Vor Bio global rights excluding China, Hong Kong, Macau and Taiwan to develop and commercialize telitacicept, a dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
Vor Bio also announced that its Board has appointed Jean-Paul Kress, as Chief Executive Officer and Chairman of the Board. This follows Robert Ang's resignation from the positions of CEO and director. Ang will continue with Vor Bio as a strategic advisor to assist in the transition through October 2025. Kress most recently served as Chief Executive Officer of MorphoSys.
Shares of Vor Bio are up 120% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
Analysen zu RemeGen Co. Ltd. Registered Shs -H- Unitary Reg S-144A
Im BX Morningcall werden folgende Aktien analysiert und erklärt – heute mit dem monatlichen Rebalancing:
NEU✅ Broadcom Inc
NEU✅ Quanta Services
NEU✅ JPMorgan Chase & Co
inklusive Rebalancing:
❌ Wolters Kluwer
❌ Thales
❌ Waste Connections
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| RemeGen Co. Ltd. Registered Shs -H- Unitary Reg S-144A | 5.90 | -0.84% |
|
| Vor Biopharma Inc Registered Shs | 1.45 | 1.40% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI beendet Handel nach Sprung über 12'000-Punkte-Marke im Plus -- DAX schliesst höher -- Wall Street letztlich uneins -- Asiens Börsen beenden Mittwochshandel uneinheitlichDer heimische Aktienmarkt zeigte sich am Mittwoch volatil. Der deutsche Aktienmarkt gewann hinzu. Der Wall Street-Handel verlief am Mittwoch uneinheitlich. In Fernost fanden die Börsen keine einheitliche Richtung.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |